Perrigo and Flamel partner on bringing new OTC format to market

DUBLIN - Perrigo and Flamel Technologies announced Monday that they have entered into an exclusive licensing agreement for LiquiTime extended release suspension.  The technology will be utilized in the development of a portfolio of extended release suspension products intended for the U.S. OTC marketplace.    

 

"LiquiTime refers to an extended release liquid suspension suitable for 12-hour to 24-hour dosing depending upon the application," Flamel CEO Mike Anderson told analysts in August. "We believe LiquiTime will be very attractive to consumers in the OTC market, particularly when compared to liquids that are immediate release and typically have to be dosed every 4 hours to 6 hours," he said.

 

Development activities for the LiquiTime pipeline include a pivotal trial for LiquiTime ibuprofen in the second half of 2015 and for guaifenesin in the first half of 2016. "Although LiquiTime ibuprofen and LiquiTime guaifenesin can be used as monotherapies, the largest market opportunity in the OTC area exist with cough-cold products that are combinations of expectorants, decongestants, antihistamines, analgesics and cough suppressants," Anderson said. 

 

"This partnership with Flamel on their innovative LiquiTime technology demonstrates our continued focus on the 'Base Plus Plus Plus' strategy," noted Joseph Papa, Perrigo chairman and CEO. During Perrigo's latest conference call with analysts, Papa explained that Perrigo's Base Plus Plus Plus business model endeavors to grow the base business by 5% to 10% while employing Perrigo's expanding platform to drive additional opportunities.